BREAKTHROUGH technologies
We are developing groundbreaking immune therapies to fundamentally transform the treatment of solid tumor cancers.
apologies while we update our content and design
the iOncologi team
BREAKING news: ioncologi acquires targimmune therapeutics
targimmune acquisition strengthens ioncologi's immunotherapy pipeline
iOncologi, Inc. and TargImmune Therapeutics (www.targimmune.com) have successfully completed a share purchase agreement, resulting in iOncologi, Inc. acquiring a majority stake in TargImmune’s shares, warrants, and options. TargImmune will continue to operate as a wholly owned subsidiary of iOncologi, Inc., maintaining its headquarters in Basel, Switzerland.
TargImmune Therapeutics is developing a first-in-class, receptor-targeted non-viral RNA delivery platform. Its lead program, IONC201, is an IND-ready biologic that achieves effective EGF receptor (EGFR)-targeted delivery of a synthetic immunomodulatory double-stranded RNA. Intravenous delivery of IONC201 induces direct killing of EGFR+ tumor cells, reprograms of the immunosuppressive tumor microenvironment, and extends survival in preclinical models of EGFR+ solid tumors. For more information, visit www.targimmune.com.
ionc101: RNA LIPID PARTICLE AGGREGATE Technology
overcoming tumor immunosuppression and tolerance via rapid and robust anti-tumor immune reprogramming
IONC101 is a groundbreaking immuno-enhancing platform based on our proprietary Multilamellar Lipid Particle Aggregate technology. IONC101 elicits a rapid and broad immune response and overcomes tumor-induced immunosuppression and tolerance, while driving long-lasting anti-tumor immunity. This next-generation RNA multilamellar therapeutic formulation has demonstrated remarkable preclinical efficacy in treating immunotherapy-resistant solid cancers. Now advancing to Phase I clinical trials, IONC101 is being evaluated as a monotherapy for refractory solid tumors.
IONC101: Efficacious as a monotherapy
IONC101 has demonstrated remarkable efficacy as a monotherapy in aggressive preclinical models of solid tumors. The survival curve shown above depicts the percent overall survival of C57Bl/6 mice (n=7-8 per group) implanted neonatally with H3K27M-positive K2 midline gliomas and treated intravenously with IONC101 (RNA-LPA) at the indicated time points. This study highlights the potent anti-tumor effects of IONC101 encoding for the H3K27M tumor antigen. Figure adapted from the landmark publication authored by iOncologi's Founder Dr. Duane A. Mitchell and colleagues at the University of Florida (Mendez-Gomez HR, DeVries A, Castillo P, et. al., Cell, 187, 2024).
IONC101: ongoing phase i CLINICAL TRIALS
IONC101 is currently being evaluated in Phase I studies across multiple solid tumor cancers. Patient enrollment is ongoing for the following cancers: newly diagnosed (nd) and recurrent (r) Adult Glioblastoma Multiforme (GBM), newly diagnosed and recurrent Pediatric (Ped) High-Grade Glioma (HGG), recurrent Pediatric Osteosarcoma, and Melanoma patients refractory to available therapies.
LeaderS in Translational Immuno-Oncology
iOncologi Founder and President, Duane A. Mitchell, MD, PhD, is an internationally renowned leader in brain tumor immunotherapy with extensive experience in the immunologic treatment of pediatric and adult brain tumors. He is the Phyllis Kottler Friedman Professor of Neurosurgery at the University of Florida. Dr. Mitchell holds four FDA-approved investigational new drug applications (INDs) governing first-in-human immunotherapy treatments. He has pioneered and led multiple novel immunotherapy clinical trials based on discoveries made in his research laboratory. His team's work in advancing brain tumor immunotherapy for glioblastoma was recognized as one of the Top 10 Clinical Research Achievements by the Clinical Research Forum in Washington, D.C. in 2016. Dr. Mitchell and Co-Founder and stem cell biologist, Catherine Flores, PhD, have partnered to develop novel stem cell-based immunotherapies for refractory cancers. Dr. Flores received her PhD in stem cell biology from the Imperial College of London and is the Principal Investigator of the Stem Cell Engineering Lab within the UF Brain Tumor Immunotherapy Program. Dr. Flores' pioneering work on the novel role of stem cells in modulating immune responses has revealed exciting new therapeutic opportunities. In addition, investigators at the University of Florida have demonstrated that iOncologi's exclusive mRNA multilamellar nanoparticle platform encompasses a systemic modifier of innate and adaptive immunity and effectively reshapes the immunosuppressive tumor microenvironment. iOncologi, Inc. is advancing disruptive treatment paradigms that hold the potential to deliver on the promise of cancer immunotherapy to the many patients who are in dire need of groundbreaking medical solutions.
ADDITIONAL INTELLECTUAL PROPERTY AND Expertise
Stem Cell Immunotherapy
iOncologi is advancing the novel use of its stem cell therapeutic in primary and metastatic brain tumors. Treatment approaches overcoming resistance to PD-1 blockade in glioblastoma and metastatic brain tumors are key areas of focus.
Immuno-Genomics
Using advances in genomics, bioinformatics, and artificial intelligence (AI) based learning, iOncologi is exploring revolutionary ways to identify novel targets for personalized immunotherapeutic treatment of refractory cancers.